Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott has announced new data from the open-label extension of the Atlas Phase III clinical trial, which showed Humira reduced the signs and symptoms of ankylosing spondylitis for up to three years of treatment among 74% of patients tested.
Subscribe to our email newsletter
Atlas was a randomized, placebo-controlled, double-blind, Phase III study conducted in the US and Europe. The study involved 315 patients with active ankylosing spondylitis (AS) who had an inadequate response to at least one non-steroidal anti-inflammatory drug or disease modifying anti-rheumatic drug. Patients received Humira 40mg subcutaneously or placebo every other week (EOW).
Results at 12 and 24 weeks showed Humira patients experienced a statistically significant reduction in signs and symptoms according to the Assessment in SpondyloArthritis International Society (ASAS) measure, or ASAS20 compared to placebo. ASAS20 represents at least a 20% improvement in at least three of the four assessments to measure patient improvement and response to therapy. At 24 weeks, all patients were switched to an open-label Humira 40mg EOW dose trial for an additional 236 weeks.
Improvement was observed through three years of treatment. After three years, 74% (174/234) of patients achieved ASAS20 and 42% (97/234) of patients achieved ASAS partial remission.